C4XD is guided by a Board with extensive expertise in drug discovery and development, clinical trials, transactions and fundraising. The team is detailed below.

Craig Fox, PhD

Craig is an experienced biologist and NIH funded Principal Investigator who has worked on and managed many drug discovery and development projects over more than 20 years in the industry, from initial target selection right through to investigating clinical efficacy and safety in Phase 2 patient studies. Craig joined C4X as Head of Biology in June 2015 before becoming Chief Scientific Officer in October later that year.

Prior to joining C4XD, Craig was Director of respiratory research at Pulmagen Therapeutics, a clinical stage company spun out of Argenta in 2010. At Pulmagen, Craig managed several of its collaborations and partnerships, including those with AstraZeneca, Chiesi, Domantis, Dr Reddy’s, Skyepharma and Teijin Pharma. Craig was part of the Etiologics team that merged with Argenta Discovery in 2004 and prior to this he worked for Bayer as a research scientist. Craig has a PhD in Respiratory Medicine from Birmingham University and a first-class biochemistry degree from the University of Surrey.

For information on the role of the Board click HERE.